Biodesix Inc (BDSX) Stock Price & Analysis
Biodesix Inc (BDSX) rose 2.74% to USD 15.36 as of June 10, 2026 at 08:45 UTC, according to Nexqual real-time market data.
BDSX last closed at USD 14.95; the session ranged USD 14.61–16 on volume of 21,970 shares. Market capitalization is $159.07M, with a 52-week range of USD 5–20.21 (NGM). Source: Nexqual, June 10, 2026 at 08:45 UTC.
Key Statistics (as of June 10, 2026 at 08:45 UTC)
| Price | USD 15.36 |
|---|---|
| Change | ▲ 2.74% (up) |
| Previous Close | USD 14.95 |
| Open | USD 14.82 |
| Day Range | USD 14.61 – 16 |
| 52-Week Range | USD 5 – 20.21 |
| Volume | 21,970 shares |
| Market Cap | $159.07M |
| Exchange | NGM |
Technical Analysis (BDSX)
Nexqual's technical model rates BDSX "NEUTRAL" based on 3 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 08:45 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.25 (neutral) |
| vs SMA50 | Above (USD 13.87) |
| MACD | 0.53 (positive) |
Analyst Ratings (BDSX)
Wall Street analysts rate BDSX "None" based on 4 analysts, with a mean price target of USD 30.5 (range USD 22–40), per Nexqual as of June 10, 2026 at 08:45 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 30.5 |
| High Target | USD 40 |
| Low Target | USD 22 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (BDSX)
| Next Earnings Date | 2026-05-04 |
|---|---|
| Revenue Estimate | $25.96M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.81 vs est -1.1 ▲ beat |
| 2025-12-31 | USD -0.49 vs est -0.87 ▲ beat |
| 2025-09-30 | USD -1.16 vs est -1.51 ▲ beat |
| 2025-06-30 | USD -1.6 vs est -1.37 ▼ miss |
Source: Nexqual, June 10, 2026 at 08:45 UTC.
Financials & Fundamentals (BDSX)
| Total Revenue | $96.10M |
|---|---|
| Revenue Growth (YoY) | +42.30% |
| Gross Margin | +81.66% |
| Operating Margin | -25.81% |
| Profit Margin | -33.26% |
| ROE | -316.53% |
| Debt / Equity | 805.61 |
| Current Ratio | 2.82 |
| Total Cash | $25.57M |
| Total Debt | $73.57M |
| Free Cash Flow | $-13.78M |
Source: Nexqual, June 10, 2026 at 08:45 UTC.
Financial Health Score (BDSX)
Nexqual rates Biodesix Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 08:45 UTC.
| Growth | Strong — Revenue +24% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 82%, operating -26% |
| Balance Sheet | Weak — $26M cash vs $74M debt |
| Cash Flow | Weak — FCF negative: -$14M, burning cash |
| Efficiency | Critical — ROE -317%, ROA -17.5% |
Ownership (BDSX)
| Insider Ownership | +41.93% |
|---|---|
| Institutional Ownership | +38.75% |
| Shares Outstanding | 10.36M |
| Float | 4.99M |
| Short % of Float | +1.80% |
Source: Nexqual, June 10, 2026 at 08:45 UTC.
Leadership (BDSX)
Biodesix Inc is led by Scott Hutton (age 53), President, CEO & Director, per Nexqual as of June 10, 2026 at 08:45 UTC.
| President, CEO & Director | Scott Hutton (age 53) |
|---|---|
| CFO, Secretary & Treasurer | Robin Harper Cowie (age 45) |
| Founder & CTO | Heinrich Roder D.Phil |
| Chief Scientific Officer | Gary Anthony Pestano (age 57) |
| Senior Director of Human Resources | Jessica Olbricht |
Major Backers & Investors (BDSX)
Notable institutional backers of Biodesix Inc include AIGH Capital Management LLC, Telemark Asset Management, LLC, Aberdeen Group plc, according to Nexqual as of June 10, 2026 at 08:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AIGH Capital Management LLC | 7.32% |
| Telemark Asset Management, LLC | 4.73% |
| Aberdeen Group plc | 4.43% |
| abrdn Healthcare Opportunities Fund | 4.43% |
| Soleus Capital Management, L.P. | 4.02% |
| Birchview Capital, LP | 2.77% |
| Opaleye Management Inc. | 2.3% |
| Marshall Wace LLP | 1.37% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.92% |
Source: Nexqual, June 10, 2026 at 08:45 UTC.
From Biodesix Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Biodesix, Inc. operates as a diagnostic solutions company.
- The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
- It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions.
- In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AFIB | Acutus Medical Inc. | USD 0 | ▲ 0% |
| ALGS | Aligos Therapeutics, Inc. | USD 5.14 | ▲ 4.68% |
| LIXT | Lixte Biotechnology Holdings, I | USD 6.87 | ▼ 1.86% |
| DMRA | Damora Therapeutics, Inc. | USD 20.96 | ▼ 0.24% |
| STTK | Shattuck Labs, Inc. | USD 4.27 | ▼ 6.77% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:45 UTC. This page is informational and not investment advice.